Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia

Ilaria S Pagani; Phuong Dang; Verity A Saunders; Jodi Braley; Angelica Thieleke; Susan Branford; Timothy P Hughes; David M Ross

doi:10.1080/10428194.2020.1772476

Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia

Leuk Lymphoma. 2020 Oct;61(10):2527-2529. doi: 10.1080/10428194.2020.1772476. Epub 2020 Jun 6.

Authors

Ilaria S Pagani^{1

2

3}, Phuong Dang¹, Verity A Saunders¹, Jodi Braley⁴, Angelica Thieleke⁵, Susan Branford^{2

4

6

7}, Timothy P Hughes^{1

2

3

5}, David M Ross^{1

2

3

5

8}

Affiliations

¹ Cancer Program, Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, Australia.
² School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, Australia.
³ Australasian Leukaemia and Lymphoma Group, Melbourne, Australia.
⁴ Genetic and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide, Australia.
⁵ Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia.
⁶ School of Biological Sciences. Faculty of Sciences, University of Adelaide, Adelaide, Australia.
⁷ School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia.
⁸ Department of Haematology and Genetic Pathology, Flinders University and Medical Centre, Adelaide, Australia.

PMID: 32508223
DOI: 10.1080/10428194.2020.1772476

No abstract available

Publication types

Letter

MeSH terms

DNA
Fusion Proteins, bcr-abl / genetics
Genomics
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
Polymerase Chain Reaction

Substances

DNA
Fusion Proteins, bcr-abl